

VISCHER ADVISES VERSANTIS ON ITS SALE TO GENTIF

Posted on 20 September 2022



Category: [Deal & transactions](#)

Tags: [Christian Wyss](#), [Christoph Niederer](#), [Gentif](#), [Matthias Staehelin](#), [Pauline Pfirter](#), [Slider](#), [Versantis](#), [Veysel Oruclar](#), [Vincent Reardon](#), [Vischer](#)



Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases, is to be sold to **Genfit**.

With this acquisition, Genfit intends to expand its product portfolio with a Phase 2 ready programme based on first-in-class scanning liposome technology, a paediatric programme focused on urea cycle disorder or an early-stage programme focused on hepatic encephalopathy. The terms of the agreement include a payment of CHF 40 million, a total of CHF 65 million of potential additional payments based on the success of clinical and regulatory milestones, and one-third of the net proceeds from the potential sale of a priority review voucher, if granted by the FDA.

VISCHER is assisting Versantis. The team is led by partner **Matthias Staehelin** (pictured right) with partner **Christian Wyss** (pictured left), **Vincent Reardon** (managing associate) and associate **Pauline Pfirter** (all corporate) as well as partner **Christoph Niederer** and associate **Veysel Oruclar** (both tax).